Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences Ships First ILUVIEN® Orders For U.K. National Health Service Hospitals

PR Newswire January 13, 2014

TrendingWallStreet.com Initiates Market Research on OSGIQ, DRI, ALIM, and GRPN

Accesswire December 20, 2013

Alimera Sciences and FDA Enter Into Labeling Discussions for ILUVIEN®, Agree Advisory Committee No Longer Necessary

PR Newswire December 18, 2013

U.K.'s NICE Issues Final Guidance Recommending Alimera Sciences' ILUVIEN®

PR Newswire December 2, 2013

Alimera Sciences Reports Third Quarter 2013 Financial Results

PR Newswire November 11, 2013

Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting

PR Newswire October 31, 2013

Alimera Sciences Receives Complete Response Letter For ILUVIEN®

PR Newswire October 18, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on ALIM, CEVA, PINC and RMD

Accesswire October 16, 2013

U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's ILUVIEN® for Chronic Diabetic Macular Edema

PR Newswire September 30, 2013

Alimera Sciences Reports Second Quarter 2013 Financial Results

PR Newswire August 12, 2013

Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results

PR Newswire August 5, 2013

France's Transparency Commission Issues Positive Opinion For Reimbursement Of ILUVIEN®

PR Newswire July 24, 2013

Alimera Sciences Added To Russell 2000®, 3000® And Global Indexes

PR Newswire July 1, 2013

Alimera Sciences Announces Issuance Of A Positive Appraisal Recommendation On ILUVIEN® For Consultation In The United Kingdom

PR Newswire June 14, 2013

InvestorsGuru.com 31 Filtered Mid-Day Market Movers Recap

Investors Guru May 19, 2013

Alimera Sciences Inc is Featured as the Daily Momentum Gainer to Watch on Smallcappower.com

Newsfile May 15, 2013

Free Research Reports on ALIM, DANG, QCOR and RVLT Issued by the Paragon Report

Marketwired May 15, 2013

Alimera Sciences Reports First Quarter 2013 Financial Results

PR Newswire May 9, 2013

Alimera Sciences Secures $20 Million Debt Facility

PR Newswire May 8, 2013

Alimera Sciences Announces First Patient Treated With Commercially Available ILUVIEN®

PR Newswire May 7, 2013